X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

NICE Urged To Make The Kidney Cancer Treatment A Priority

Content Team by Content Team
7th February 2023
in News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

NICE, the National Institute for Health and Care Excellence, has received a plea from the Kidney Cancer UK to bring about guidelines on the diagnosis and treatment of kidney cancer as a significant priority.

Although NHS England has commissioned NICE to go through the urgent work, the recent results of a survey conducted by Kidney Cancer UK suggest that the policies have to be framed sooner rather than later.

The survey brings to light the fact that nearly a third of patients have waited for their turn in excess of three months, right from first presenting to a doctor to being given a proper diagnosis. Moreover, as per the survey, 22% of the patients were initially misdiagnosed.

The charity also highlights the need to ensure that kidney cancer is identified early and how it could be rectified by seamless guidelines, both on referrals as well as diagnosis.

The survey puts forth the fact that over 40% of the kidney cancer patients are still in the queue with three to five weeks left until their scan results. The survey, surprisingly, also brings up the fact that 48% of kidney cancer in patients was discovered incidentally through a scan that was not predominantly done for that.

It is well to noted that patients were unhappy with the fact that when the diagnosis was made, the method used to share the result with them was uncalled for—it was often done over the phone.

The University of Cambridge’s Professor Grant Stewart stated in his analysis that the nature of the statistics in this survey has been deeply concerning because these diagnoses and services are occurring post-COVID-19. The fact that 40% of the patients are diagnosed at stage 3 or stage 4 downplays the NHS’s long-term plan of diagnosing three out of four cancers at stage 1 or stage 2 by 2028.

Associate Professor of Radiology from the University Hospital of Southampton, Dr. David Breen opines that one needs to get into less invasive and more effective treatments like Cryoablation when it comes to sub 4-5cms kidney tumours. This surely reflects the need of the patient and significantly spares the kidney function in the background. Although ablation might not be perfect for all kidney cancer patients, it must be discussed in the case of smaller kidney cancers.

Previous Post

ABPI In UK Sees Possibility of Revenue Clawback Rate Rise

Next Post

Twelve Digit National Drug Code Gets Proposed By The FDA

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
Usual Pharma Compliance Issues Noted In FDA Warning Letters

Twelve Digit National Drug Code Gets Proposed By The FDA

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In